Contineum Therapeutics’ (CTNM) “Equal Weight” Rating Reiterated at Morgan Stanley

Morgan Stanley reiterated their equal weight rating on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research report report published on Thursday, MarketBeat reports. They currently have a $14.00 price target on the stock, down from their previous price target of $23.00.

Other research analysts also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Thursday, September 25th. Leerink Partners assumed coverage on Contineum Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $22.00 target price for the company. Royal Bank Of Canada decreased their target price on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research report on Friday, November 21st. Robert W. Baird dropped their price target on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Monday, November 24th. Finally, Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Contineum Therapeutics Stock Up 1.5%

CTNM opened at $9.31 on Thursday. The firm’s 50-day moving average price is $11.24 and its 200-day moving average price is $9.59. Contineum Therapeutics has a 52-week low of $3.35 and a 52-week high of $13.57. The company has a market cap of $271.67 million, a P/E ratio of -4.14 and a beta of 1.21.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.13. On average, research analysts anticipate that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Trading of Contineum Therapeutics

A number of institutional investors have recently modified their holdings of the business. Strs Ohio purchased a new position in Contineum Therapeutics in the first quarter worth $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth $43,000. Marex Group plc acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth $45,000. Bridgeway Capital Management LLC purchased a new position in shares of Contineum Therapeutics in the 2nd quarter valued at about $76,000. Finally, Jane Street Group LLC acquired a new stake in shares of Contineum Therapeutics in the second quarter valued at about $81,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.